Trinity Street Asset Management LLP Raises Stock Position in Charles River Laboratories Intl. Inc (NYSE:CRL)

Trinity Street Asset Management LLP raised its holdings in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 28.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 185,775 shares of the medical research company’s stock after acquiring an additional 41,400 shares during the quarter. Charles River Laboratories Intl. makes up 3.8% of Trinity Street Asset Management LLP’s portfolio, making the stock its 16th largest holding. Trinity Street Asset Management LLP owned 0.38% of Charles River Laboratories Intl. worth $24,591,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Charles River Laboratories Intl. by 1.6% during the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock worth $661,344,000 after acquiring an additional 72,827 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 7.5% during the 2nd quarter. AQR Capital Management LLC now owns 2,239,921 shares of the medical research company’s stock worth $317,845,000 after acquiring an additional 157,160 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Charles River Laboratories Intl. by 49.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock worth $138,804,000 after acquiring an additional 323,625 shares during the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of Charles River Laboratories Intl. by 5.1% during the 2nd quarter. TimesSquare Capital Management LLC now owns 907,850 shares of the medical research company’s stock worth $128,824,000 after acquiring an additional 44,275 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Charles River Laboratories Intl. by 5.1% during the 2nd quarter. Bank of America Corp DE now owns 471,966 shares of the medical research company’s stock worth $66,972,000 after acquiring an additional 22,821 shares during the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.

Shares of CRL stock traded up $0.69 on Thursday, hitting $126.74. 34,381 shares of the stock traded hands, compared to its average volume of 358,028. The firm has a market cap of $6.17 billion, a price-to-earnings ratio of 21.02, a PEG ratio of 1.94 and a beta of 1.09. Charles River Laboratories Intl. Inc has a 52 week low of $103.00 and a 52 week high of $149.07. The firm has a 50 day simple moving average of $132.92 and a two-hundred day simple moving average of $134.29. The company has a debt-to-equity ratio of 1.47, a current ratio of 1.59 and a quick ratio of 1.38.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.08. The firm had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. Sell-side analysts forecast that Charles River Laboratories Intl. Inc will post 6.52 EPS for the current year.

Several research analysts have recently weighed in on the stock. Credit Suisse Group set a $138.00 price target on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a research note on Friday, September 13th. Bank of America cut shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 price target on the stock. in a research note on Friday, October 18th. ValuEngine cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. SunTrust Banks lifted their price target on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $150.46.

In other news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the sale, the insider now directly owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.80% of the stock is owned by company insiders.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: How is a price target determined?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.